carmustine has been researched along with Ovarian Neoplasms in 21 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Excerpt | Relevance | Reference |
---|---|---|
"The growth inhibitory effects, the reduction of [3H]-TdR incorporation and the perturbation of the cell cycle induced by the new agent mitozolomide on the M14 human melanoma cell line and on the SW626 human ovarian cancer cell line were compared to those produced by BCNU." | 3.67 | Mitozolomide activity on human cancer cells in vitro. ( D'Incalci, M; Erba, E; Landoni, F; Lorico, A; Mangioni, C; Morasca, L; Pepe, S; Ubezio, P, 1986) |
"In the human ovarian cancer lines SK-OV-3 and OAW 42, O6-AGT activity was 337." | 1.29 | Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU. ( Magull-Seltenreich, A; Zeller, WJ, 1995) |
"on post-surgical spontaneous metastases of a non-immunogenic tumour." | 1.28 | Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour. ( Acerbis, G; Cleris, L; Formelli, F; Parmiani, G; Rodolfo, M, 1992) |
"AC = adriamycin and cyclophosphamide in ovarian cancer." | 1.27 | Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide. ( Amunni, G; Bonazza, M; Branconi, F; Massi, GB; Mazzei, T; Scarselli, G, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 10 (47.62) | 18.7374 |
1990's | 8 (38.10) | 18.2507 |
2000's | 3 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Perego, P | 1 |
Gatti, L | 1 |
Righetti, SC | 1 |
Beretta, GL | 1 |
Carenini, N | 1 |
Corna, E | 1 |
Dal Bo, L | 1 |
Tinelli, S | 1 |
Colangelo, D | 1 |
Leone, R | 1 |
Apostoli, P | 1 |
Lombardi, L | 1 |
Beggiolin, G | 1 |
Piazzoni, L | 1 |
Zunino, F | 1 |
Paik, J | 1 |
Duncan, T | 1 |
Lindahl, T | 1 |
Sedgwick, B | 1 |
D'Incalci, M | 2 |
Torti, L | 1 |
Damia, G | 1 |
Erba, E | 2 |
Morasca, L | 2 |
Garattini, S | 1 |
Cornbleet, MA | 1 |
Leonard, RC | 1 |
Smyth, JF | 1 |
Mazzei, T | 1 |
Bonazza, M | 1 |
Amunni, G | 1 |
Scarselli, G | 1 |
Branconi, F | 1 |
Massi, GB | 1 |
Presant, CA | 1 |
Bartolucci, A | 1 |
Magull-Seltenreich, A | 1 |
Zeller, WJ | 2 |
Strumberg, D | 1 |
Harstrick, A | 1 |
Doll, K | 1 |
Hoffmann, B | 1 |
Seeber, S | 1 |
Bernges, F | 1 |
Fruehauf, JP | 2 |
Zonis, S | 2 |
al-Bassam, M | 2 |
Kyshtoobayeva, A | 2 |
Dasgupta, C | 2 |
Milovanovic, T | 2 |
Parker, RJ | 2 |
Buzaid, AC | 2 |
Mandanas, RA | 1 |
Saez, RA | 1 |
Epstein, RB | 1 |
Confer, DL | 1 |
Selby, GB | 1 |
Bible, KC | 1 |
Boerner, SA | 1 |
Kirkland, K | 1 |
Anderl, KL | 1 |
Bartelt, D | 1 |
Svingen, PA | 1 |
Kottke, TJ | 1 |
Lee, YK | 1 |
Eckdahl, S | 1 |
Stalboerger, PG | 1 |
Jenkins, RB | 1 |
Kaufmann, SH | 1 |
Salmon, SE | 1 |
Hamburger, AW | 1 |
Soehnlen, B | 1 |
Durie, BG | 1 |
Alberts, DS | 1 |
Moon, TE | 1 |
Acerbis, G | 1 |
Cleris, L | 1 |
Rodolfo, M | 1 |
Parmiani, G | 1 |
Formelli, F | 1 |
Lau, DH | 1 |
Lewis, AD | 1 |
Ehsan, MN | 1 |
Sikic, BI | 1 |
Pepe, S | 1 |
Ubezio, P | 1 |
Lorico, A | 1 |
Mangioni, C | 1 |
Landoni, F | 1 |
Facchini, V | 1 |
Gadducci, A | 1 |
Bogi, G | 1 |
Colombi, L | 1 |
Basile, AG | 1 |
Ballantini, M | 1 |
De Pasquale, F | 1 |
Fioretti, P | 1 |
Marsh, JC | 1 |
DeConti, RC | 1 |
Hubbard, SP | 1 |
Jorgensen, EO | 1 |
Malkasian, GD | 1 |
Webb, MJ | 1 |
Hahn, RG | 1 |
Godfrey, TE | 1 |
King, A | 1 |
Rentschler, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
Intervention | Participants (Count of Participants) |
---|---|
Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
Intervention | months (Median) |
---|---|
Bendamustine/Ofatumumab | 10.5 |
1 review available for carmustine and Ovarian Neoplasms
Article | Year |
---|---|
High-dose alkylating agent therapy: a review of clinical experiences.
Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug; | 1984 |
3 trials available for carmustine and Ovarian Neoplasms
Article | Year |
---|---|
Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplati | 1998 |
Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Topics: Adenocarcinoma; Adenoma, Islet Cell; Adolescent; Adrenal Gland Neoplasms; Adult; Alkylating Agents; | 1971 |
Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
Topics: Carmustine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Injections, Intravenous; Ova | 1973 |
17 other studies available for carmustine and Ovarian Neoplasms
Article | Year |
---|---|
Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Base Pair Mismatch; Carmustine; Checkpoint Kinase 1; Cisplatin; Cy | 2003 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Ge | 2005 |
Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide.
Topics: Animals; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Cyclophosphamide; Dacarbazine; Dr | 1983 |
Polychemotherapy in ovarian cancer: treatment with Adriamycin, BCNU and cyclophosphamide vs. Adriamycin and cyclophosphamide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; | 1984 |
Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
Topics: Adenocarcinoma; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cycloph | 1983 |
Inhibition of O6-alkylguanine-DNA alkyltransferase in animal and human ovarian tumor cell lines by O6-benzylguanine and sensitization to BCNU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cystadenocarcinoma, | 1995 |
Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine | 1996 |
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cell Survival; Cisplatin; DNA D | 1996 |
Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Breast Neoplasms; Buthionine Sul | 1997 |
Melanin content and downregulation of glutathione S-transferase contribute to the action of L-buthionine-S-sulfoximine on human melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buthionine Sulfoximine; Carmustine | 1998 |
Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.
Topics: Antineoplastic Agents; Carmustine; Chromosome Aberrations; Chromosome Mapping; Cisplatin; DNA Adduct | 2000 |
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
Topics: Antineoplastic Agents; Bleomycin; Carmustine; Clone Cells; Doxorubicin; Drug Resistance; Female; Hem | 1978 |
Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.
Topics: Animals; Carmustine; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administratio | 1992 |
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
Topics: Bleomycin; Blotting, Western; Carmustine; Cisplatin; Cross Reactions; Dinitrochlorobenzene; DNA; DNA | 1991 |
Mitozolomide activity on human cancer cells in vitro.
Topics: Aged; Antineoplastic Agents; Carmustine; Cell Cycle; Cell Line; Dose-Response Relationship, Drug; Fe | 1986 |
Polychemotherapy with carmustine, cyclophosphamide plus adriamycin in the treatment of advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; | 1985 |
1,3-Bis (2-chloroethyl)-1-nitrosourea: effects on advanced ovarian carcinoma.
Topics: Adult; Aged; Blood Platelets; Carmustine; Cystadenocarcinoma; Drug Resistance; Female; Humans; Leuko | 1973 |